Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma

被引：0
|
作者：
Kim, In Ae [1 ]
Kim, Hee Jung [1 ]
Hur, Jae Young [1 ]
Lee, Seung En [1 ]
Park, Jung Hoon [2 ]
Lee, Song Am [1 ]
Hwang, Jae Jun [1 ]
Kim, Wan Seop [1 ]
Lee, Kye Young [1 ]
机构：
[1] Konkuk Univ, Med Ctr, Seoul, South Korea
[2] Macrogen Inc, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5896
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma
    Zheng, X.
    Huang, C.
    Lin, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Combination Therapy for EGFR-Mutated Lung Cancer
    Wu, Yi-Long
    Zhou, Qing
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 2005 - 2007
  • [43] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [44] Circulating DNA in EGFR-mutated lung cancer
    Singh, Aditi P.
    Li, Shenduo
    Cheng, Haiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (18)
  • [45] FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma
    Shang, Zhi
    Niu, Xiaomin
    Zhang, Kewei
    Qiao, Zhi
    Liu, Sha
    Jiang, Xiaoteng
    Cao, Chengxi
    Lu, Shun
    Xiao, Hua
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2019, 97 (12): : 1657 - 1668
  • [46] FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma
    Zhi Shang
    Xiaomin Niu
    Kewei Zhang
    Zhi Qiao
    Sha Liu
    Xiaoteng Jiang
    Chengxi Cao
    Shun Lu
    Hua Xiao
    Journal of Molecular Medicine, 2019, 97 : 1657 - 1668
  • [47] Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
    Luo, Jia-Wei
    Guo, Yan-Hua
    Wu, Feng-Ying
    Li, Xue-Fei
    Sun, Xue-Cheng
    Wang, Jia-Lu
    Zhou, Cai-Cun
    DISEASE MARKERS, 2021, 2021
  • [48] GefitinibAcquired drug resistance in EGFR-mutated bone metastasised lung adenocarcinoma: case report
    Reactions Weekly, 2019, 1778 (1) : 214 - 214
  • [49] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
    Patil, Vijay Maruti
    Noronha, Vanita
    Joshi, Amit
    Choughule, Anuradha Bharat
    Bhattacharjee, Atanu
    Kumar, Rajiv
    Goud, Supriya
    More, Sucheta
    Ramaswamy, Anant
    Karpe, Ashay
    Pande, Nikhil
    Chandrasekharan, Arun
    Goel, Alok
    Talreja, Vikas
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Prabhash, Kumar
    ESMO OPEN, 2017, 2 (01)
  • [50] An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
    Zhang, X.
    Wu, Y.
    Hu, Y.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S415 - S415
12345